Keystone Capital, a private investment firm, agreed to acquire 10k shares of series b convertible stock of Evofem Biosciences, a commercial stage biopharmaceutical company, for $10m. "This financing provides us with a runway into the first quarter of 2022 as we accelerate Phexxi's growth trajectory and work to deliver long-term value for shareholders and women," Saundra Pelletier, Evofem CEO.